Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Foà R[au]:

Search results

Items: 1 to 50 of 728

1.

Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.

Prezzo A, Cavaliere FM, Bilotta C, Pentimalli TM, Iacobini M, Cesini L, Foà R, Mauro FR, Quinti I.

Leuk Res. 2019 Oct 3;87:106233. doi: 10.1016/j.leukres.2019.106233. [Epub ahead of print]

PMID:
31639635
2.

Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients.

Serrao A, Santoro C, Foà R, Chistolini A.

HIV Med. 2019 Oct 16. doi: 10.1111/hiv.12803. [Epub ahead of print] No abstract available.

PMID:
31618519
3.

In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.

Baccarani M, Iacobucci I, Chiaretti S, Foà' R, Balasubramanian P, Paietta E, Foroni L, Jeromin S, Izzo B, Spinelli O, Varma N, Menif S, Terragna C, Seth T, Bidet A, Coriu D, Lunghi F, Mayer J, Scappini B, Langabeer S, Maier J, Burt E, Candoni A, Albano F, Luppi M, Zupan I, Lion T, Zadro R, di Raimondo F, Popak B, Rege-Cambrin G, Annunziata M, Ayala A, Salinas-Viedma V, Ines Prado A, Milner B, Galimberti S, Janssen J, Polli V, Comba L, Borsellino B, Annibali O, Crugnola M, Passamonti F.

Leukemia. 2019 Oct 8. doi: 10.1038/s41375-019-0591-9. [Epub ahead of print] No abstract available.

PMID:
31595038
4.

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.

Cesini L, Carmosino I, Breccia M, De Benedittis D, Mohamed S, De Luca ML, Colafigli G, Molica M, Scalzulli E, Massaro F, Mariggiò E, Rizzo L, Loglisci MG, Scamuffa MC, Vozella F, Diverio D, Mancini M, Alimena G, Foà R, Latagliata R.

Oncol Res Treat. 2019 Oct 8:1-5. doi: 10.1159/000502801. [Epub ahead of print]

PMID:
31593970
5.

Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript.

Fazio F, Barberi W, Cazzaniga G, Fazio G, Messina M, Della Starza I, De Propris MS, Mancini F, Mohamed S, Del Giudice I, Chiaretti S, Moleti ML, Guarini A, Foà R, Testi AM.

Leuk Lymphoma. 2019 Sep 27:1-4. doi: 10.1080/10428194.2019.1668938. [Epub ahead of print] No abstract available.

PMID:
31558067
6.

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, Cappelli LV, Ilari C, Cafforio L, Guarini A, Foà R.

Front Oncol. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689. eCollection 2019. Review.

7.

CMV Management with Specific Immunoglobulins: A Multicentric Retrospective Analysis on 92 Allotransplanted Patients.

Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, Barbieri W, Bruzzese A, Leotta S, Carotti A, Pierini A, Bernardi S, Morello E, Polverelli N, Turra A, Cattina F, Gandolfi L, Rambaldi B, Lorentino F, Serio F, Milone G, Velardi A, Foà R, Ciceri F, Russo D, Peccatori J.

Mediterr J Hematol Infect Dis. 2019 Sep 1;11(1):e2019048. doi: 10.4084/MJHID.2019.048. eCollection 2019.

8.

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot JL, Tausch E, Trunzer K, Robson S, Gresko E, Böttcher S, Foà R, Stilgenbauer S, Leblond V.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0554-1. [Epub ahead of print]

PMID:
31455851
9.

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.

Della Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA, Soscia R, Messina M, Vitale A, Guarini A, Foà R.

Front Oncol. 2019 Aug 7;9:726. doi: 10.3389/fonc.2019.00726. eCollection 2019. Review.

10.

Maintenance therapy in AML: The past, the present and the future.

Molica M, Breccia M, Foa R, Jabbour E, Kadia TM.

Am J Hematol. 2019 Nov;94(11):1254-1265. doi: 10.1002/ajh.25620. Epub 2019 Sep 11. Review.

PMID:
31429099
11.

Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: a single-center experience.

Bruzzese A, Santoro C, Baldacci E, Ferretti A, Pieroni S, Serrao A, Foà R, Chistolini A.

Blood Coagul Fibrinolysis. 2019 Sep;30(6):304-307. doi: 10.1097/MBC.0000000000000835.

PMID:
31419212
12.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).

Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M, Bruno B, Sora F, Bernasconi P, Saccardi R, Foà R, Sessa M, Bresciani P, Giglio F, Picardi A, Busca A, Sica S, Perruccio K, Zucchetti E, Diral E, Iori AP, Colombo AA, Tringali S, Santarone S, Irrera G, Mancini S, Zallio F, Malagola M, Albano F, Carella AM, Olivieri A, Tecchio C, Dominietto A, Vacca A, Sorasio R, Orciuolo E, Risitano AM, Leotta S, Cortelezzi A, Mammoliti S, Oldani E, Bonifazi F; GITMO.

Biol Blood Marrow Transplant. 2019 Aug 7. pii: S1083-8791(19)30509-9. doi: 10.1016/j.bbmt.2019.07.037. [Epub ahead of print]

PMID:
31400502
13.

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.

Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S.

Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.

PMID:
31395600
14.

Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.

Pulsoni A, Della Starza I, Cappelli LV, Tosti ME, Annechini G, Cavalli M, De Novi LA, D'Elia GM, Grapulin L, Guarini A, Del Giudice I, Foà R.

Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16125. [Epub ahead of print]

PMID:
31385309
15.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D.

Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550. [Epub ahead of print]

16.

Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.

Ferretti A, Baldacci E, Miulli E, Canichella M, Di Rocco A, Pulsoni A, Martelli M, Serrao A, Chistolini A, Gabriella Mazzucconi M, Foà R, Santoro C.

Br J Haematol. 2019 Sep;186(6):e217-e219. doi: 10.1111/bjh.16114. Epub 2019 Jul 31. No abstract available.

PMID:
31364154
17.

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L.

Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31. No abstract available.

PMID:
31364153
18.

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.

Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L.

Hematol Oncol. 2019 Jul 23. doi: 10.1002/hon.2655. [Epub ahead of print] No abstract available.

PMID:
31335982
19.

Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network.

Hematol Oncol. 2019 Jul 19. doi: 10.1002/hon.2652. [Epub ahead of print]

PMID:
31325190
20.

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.

Colafigli G, Scalzulli E, Porrazzo M, Diverio D, Loglisci MG, Latagliata R, Guarini A, Foà R, Breccia M.

Hematol Oncol. 2019 Jul 19. doi: 10.1002/hon.2650. [Epub ahead of print] No abstract available.

PMID:
31321792
21.

Direct Oral Anticoagulants in Patients Affected by Major Congenital Thrombophilia.

Serrao A, Lucani B, Mansour D, Ferretti A, Baldacci E, Santoro C, Foà R, Chistolini A.

Mediterr J Hematol Infect Dis. 2019 Jul 1;11(1):e2019044. doi: 10.4084/MJHID.2019.044. eCollection 2019.

22.

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.

Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R.

Leuk Lymphoma. 2019 Jul 12:1-11. doi: 10.1080/10428194.2019.1639170. [Epub ahead of print]

PMID:
31298059
23.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

24.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.

Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L.

Cancers (Basel). 2019 Jun 26;11(7). pii: E896. doi: 10.3390/cancers11070896.

25.

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L.

Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18.

PMID:
31209327
26.

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.

Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E, Bonifacio M, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G, Martinelli V, Cavo M, Pane F, De Stefano V, Foà R, Palandri F.

Ann Hematol. 2019 Aug;98(8):1933-1936. doi: 10.1007/s00277-019-03727-6. Epub 2019 Jun 14.

PMID:
31201513
27.

Platelet activation and multidrug resistance protein-4 expression in children and adolescents with different subtypes of primary thrombocythemia.

Giona F, Massimi I, Guarino ML, Santopietro M, Laurino M, Temperilli F, Palumbo G, Foà R, Pulcinelli FM.

Haematologica. 2019 Jun 6. pii: haematol.2019.226266. doi: 10.3324/haematol.2019.226266. [Epub ahead of print]

28.

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1919-1925. doi: 10.1007/s00277-019-03724-9. Epub 2019 Jun 5.

PMID:
31168652
29.

Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.

Santopietro M, Miano M, Palumbo G, Zhang K, Cardarelli L, Chiaretti S, Peragine N, Nanni M, Diverio D, Mancini F, Testi AM, Moleti ML, Foà R, Giona F.

Acta Haematol. 2019;142(3):185-186. doi: 10.1159/000497137. Epub 2019 May 21. No abstract available.

PMID:
31112981
30.

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia P, Foà R, Caligaris-Cappio F, Gobbi M.

Haematologica. 2019 Oct;104(10):2053-2060. doi: 10.3324/haematol.2018.205930. Epub 2019 May 16.

31.

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Molica M, Colafigli G, Scalzulli E, Alunni Fegatelli D, Chiatamone Ranieri S, Rizzo L, Diverio D, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1891-1904. doi: 10.1007/s00277-019-03706-x. Epub 2019 May 11.

PMID:
31079264
32.

Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

Andriani A, Elli E, Trapè G, Villivà N, Fianchi L, Di Veroli A, Niscola P, Centra A, Anaclerico B, Montanaro G, Martini V, Aroldi A, Carmosino I, Voso MT, Breccia M, Montanaro M, Foà R, Latagliata R.

Hematol Oncol. 2019 Aug;37(3):291-295. doi: 10.1002/hon.2635. Epub 2019 May 30.

PMID:
31050810
33.

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.

Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A.

Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1607325. [Epub ahead of print] No abstract available.

PMID:
31050551
34.

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.

Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A, Bonifacio M, Fozza C, Trawinska MM, Cattaneo D, Elena C, Baratè C, De Gregorio F, Molica M, La Nasa G, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1.

PMID:
31044260
35.

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.

Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M.

Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17.

PMID:
31029498
36.

Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients.

Moleti ML, Al-Jadiry MF, Shateh WA, Al-Darraji AF, Mohamed S, Uccini S, Piciocchi A, Foà R, Testi AM, Al-Hadad S.

Leuk Lymphoma. 2019 May;60(5):1224-1233. doi: 10.1080/10428194.2018.1519810.

PMID:
30997873
37.

The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPO-RA.

Porrazzo M, Baldacci E, Ferretti A, Miulli E, Chistolini A, Pecci A, Mazzucconi MG, Foà R, Santoro C.

Haemophilia. 2019 Jul;25(4):e288-e290. doi: 10.1111/hae.13757. Epub 2019 Apr 17. No abstract available.

PMID:
30993846
38.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619. [Epub ahead of print]

PMID:
30985017
39.

[Assessment of burnout in health care personnel in hematological unit of a teaching hospital].

Mannocci A, Sestili C, Carnevale F, Minotti C, De Giusti M, Villari P, Foà R, Cartoni C, La Torre G.

G Ital Med Lav Ergon. 2019 Mar;41(1):45-51. Italian.

40.

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M.

Hematol Oncol. 2019 Aug;37(3):296-302. doi: 10.1002/hon.2606. Epub 2019 Apr 17.

41.

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Cuneo A, Foà R.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019024. doi: 10.4084/MJHID.2019.024. eCollection 2019.

42.

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Molica M, Scalzulli E, Colafigli G, Foà R, Breccia M.

Ther Adv Hematol. 2019 Mar 1;10:2040620719826444. doi: 10.1177/2040620719826444. eCollection 2019. Review.

43.

Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol.

La Rocca U, Perrone MP, Piciocchi A, Cinti P, Barberi W, Gozzer M, Baftii MS, Torelli GF, Quattrocchi L, Gesuiti P, Lattanzi R, Cavallari C, Ricci R, Laurenti L, Foà R, Girelli G, Iori AP.

Bone Marrow Transplant. 2019 Oct;54(10):1717-1720. doi: 10.1038/s41409-019-0497-1. Epub 2019 Mar 4. No abstract available.

PMID:
30833741
44.

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foà R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R.

Hematology. 2019 Dec;24(1):337-348. doi: 10.1080/16078454.2019.1567654.

45.

Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia.

Giudice ID, Foà R.

Haematologica. 2019 Feb;104(2):219-221. doi: 10.3324/haematol.2018.207399. No abstract available.

46.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P.

Bone Marrow Transplant. 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21.

PMID:
30664723
47.

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Breccia M, Foà R.

Expert Rev Hematol. 2019 Feb;12(2):81-87. doi: 10.1080/17474086.2019.1562332. Epub 2019 Jan 7.

PMID:
30572725
48.

BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?

Chiaretti S, Messina M, Foà R.

Cancer. 2019 Jan 15;125(2):194-204. doi: 10.1002/cncr.31848. Epub 2018 Dec 18. Review.

PMID:
30561755
49.

Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia.

Chiaretti S, Foà R.

Eur J Intern Med. 2018 Dec;58:22-27. doi: 10.1016/j.ejim.2018.05.028. Review.

PMID:
30527919
50.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542

Supplemental Content

Support Center